Dolcia Prima Allulose from Tate & Lyle PLC – low calorie sweetness for reformulated drinks – AD HOC NEWS

AD HOC NEWS

Image Credit: AD HOC NEWS

Please find more details at AD HOC NEWS

Summary

Dolcia Prima Allulose cuts sugar calories while keeping a familiar sweetness profile for modern soft drinks and dairy snacks. This bestseller drives the price of Tate & Lyle shares (ISIN GB0008707753).

Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-30, 02:38. Details…

Source: AD HOC NEWS

Read More

(0)

AI News Q&A (Free Content)

This content is freely available. No login required. Disclaimer: Following content is AI generated from various sources including those identified below. Always check for accuracy. No content here is an advice. Please use the contact button to share feedback about any inaccurate content generated by AI. We sincerely appreciate your help in this regard.

Q1: What is Dolcia Prima Allulose and how does it benefit food manufacturers?

A1: Dolcia Prima Allulose is a low-calorie sweetener developed by Tate & Lyle, offering the taste and texture of sugar with 90% fewer calories. It enables food manufacturers to create low-calorie versions of their products without sacrificing taste or texture. This ingredient is particularly useful in formulating beverages, baked goods, and dairy desserts, providing a similar mouthfeel to sugar and facilitating easier product formulation.

Q2: How does allulose differ from traditional sugars in terms of metabolic impact?

A2: Allulose is absorbed differently by the body compared to traditional sugars. It does not raise insulin levels, and is not metabolized to glucose, which means it has minimal impact on blood sugar levels. This makes it a suitable alternative for people managing their blood sugar, such as those with diabetes.

Q3: What are the regulatory stances on allulose's use in food products?

A3: The U.S. Food and Drug Administration (FDA) has recognized allulose as Generally Recognized as Safe (GRAS) for use in various food categories. It is exempt from being listed as a sugar on Nutrition and Supplement Facts labels, although it is listed as a carbohydrate. This regulatory stance supports its use as a sugar substitute in a variety of food and beverage applications.

Q4: What are the results of recent studies on allulose's impact on metabolic health?

A4: Recent studies, such as those published in 2026, have shown that allulose significantly reduces postprandial glucose and insulin levels while increasing GLP-1 concentrations. These effects highlight allulose's potential as a functional ingredient in managing glycemic and metabolic health.

Q5: What historical developments led to the commercial availability of allulose?

A5: Allulose was first identified in the 1940s, but industrial production became feasible only after the discovery of necessary enzymes in the 1990s. Its commercial use as a low-calorie sweetener gained momentum in the 21st century, following regulatory approvals and recognition of its health benefits.

Q6: How does allulose compare to other sweeteners in terms of consumer preference and taste?

A6: Studies have shown that foods and beverages formulated with Dolcia Prima Allulose often match or exceed the taste preference of their full-sugar counterparts. Allulose provides a clean, sweet taste with only a fraction of the calories, making it an attractive option for consumers seeking healthier alternatives.

Q7: Are there any potential side effects of consuming allulose, and what are the consumption guidelines?

A7: Allulose is generally well-tolerated, with studies indicating it can be consumed safely up to 30 grams per day without significant gastrointestinal side effects. This tolerance level supports its safe inclusion in various dietary products.

References:

  • Differential Modulation of Postprandial Glycemic, Incretin, and Satiety Responses by Low-Digestible Carbohydrates in Humans: An Exploratory Investigation.
  • Effects of Allulose vs Aspartame Consumption on Postprandial Glucagon-Like Peptide-1 Profiles and Metabolic Health: Protocol for a Randomized, Crossover, Double-Blind, Placebo-Controlled Trial.